Sling Therapeutics hires new CCO
ANN ARBOR–Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease, announced the appointment of Ken Lock as …
Pharma startup announces next stage of clinical trial for new cancer drug
GROSSE POINTE FARMS—SciTech Development LLC, a clinical-stage pharmaceutical company specializing in oncology, announced the initiation of the next stage of its clinical trial for their lead drug candidate, ST-001 nanoFenretinide. …
Esperion, Daiichi Sankyo Europe settle litigation
ANN ARBOR–Esperion Therapeutics Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH, the Europe-based organization of the Japanese pharmaceutical company Daiichi Sankyo Co. Ltd., announced a $125 million amendment to their collaboration, which …
Caeregen wins $1.4M SBIR grant for new eye drug
ROCHESTER–Caeregen Therapeutics announced that it has been awarded a $1.4 million Phase 2 Small Business Innovation Research grant from the National Institutes of Health and its National Eye Institute to …
Zivo Bioscience receives $1 million bridge financing
BLOOMFIELD HILLS–Zivo Bioscience Inc. (NASDAQ: ZIVO), a biotech and agriculture-tech research and development company developing medicines and nutritional products from algae cultures, announced a $1 million unsecured six-month loan from …
Abionyx Pharma announces new strategy, promising preclinical results
LAKELAND–Abionyx Pharma, a startup biotech company with operations in Michigan and France, announced its strategy in ophthalmology and new positive preclinical results in two technological platforms: apotherapy and biovectorisation. Cyrille …
Gilead, Evoq Therapeutics announce $600M+ collaboration to boost immunotherapies
ANN ARBOR—Evoq Therapeutics Inc., the Ann Arbor-based immune disease drug development firm, and Foster City, Calif.-based Gilead Sciences Inc. (Nasdaq: GILD) have announced a collaboration and licensing agreement to advance …
Rockwell Medical to suspend pharma development, concentrate on revenue
WIXOM–Rockwell Medical Inc. (Nasdaq: RMTI), the Wixom-based developer of products for patients suffering from blood and kidney disorders, announced it would suspend develop of new pharmaceutical products, and concentrate instead …
BlueWillow Biologics sees positive results from Phase 1 trial of anthrax vaccine
ANN ARBOR—BlueWillow Biologics Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine …
New CEO at GR’s Tetra Therapeutics
GRAND RAPIDS—Officials at Tetra Therapeutics, a pharma startup developing drugs to treat brain disorders associated with cognitive and memory deficits, announced that CEO Mark Gurney had retired effective June 30. …